DMPK products at Preci
Preci’s DMPK product suite is engineered to support rigorous drug metabolism and pharmacokinetic (DMPK) analysis, utilizing high-quality human hepatocytes, human liver microsomes, and other subcellular fractions. Designed for precision and reproducibility, our human-derived cellular assays, including hepatocyte and microsomal assays, are sourced from an extensive clinical network and undergo stringent quality control to ensure batch-to-batch consistency. With single-donor and pooled hepatocyte batches reserved for long-term use, our DMPK products provide unparalleled reliability for studies focused on metabolic clearance, toxicity, and drug-drug interactions. Partnering with Preci grants researchers access to specialized reagents and consumables optimized for complex DMPK workflows, simplifying experimental processes while supporting comprehensive and reproducible results.
Preci’s DMPK product suite is engineered to support rigorous drug metabolism and pharmacokinetic (DMPK) analysis, utilizing high-quality human hepatocytes, human liver microsomes, and other subcellular fractions. Designed for precision and reproducibility, our human-derived cellular assays, including hepatocyte and microsomal assays, are sourced from an extensive clinical network and undergo stringent quality control to ensure batch-to-batch consistency. With single-donor and pooled hepatocyte batches reserved for long-term use, our DMPK products provide unparalleled reliability for studies focused on metabolic clearance, toxicity, and drug-drug interactions. Partnering with Preci grants researchers access to specialized reagents and consumables optimized for complex DMPK workflows, simplifying experimental processes while supporting comprehensive and reproducible results.
Applications
Hepatic clearance determination
Metabolites identifications
Uptake and efflux transporter induction and inhibition
CYP induction
The isolation of human hepatocytes is a meticulous process involving stringent protocols to preserve cell functionality and viability. From donor tissue preparation to enzymatic digestion, each step demands precision and expertise to ensure high-quality cells for research. This labor-intensive procedure is the foundation for creating reliable models for drug metabolism and pharmacokinetics (DMPK) studies.
Achieving industry-standard values for CYPs and Phase II enzymes is critical for successful experimental outcomes. Preci prioritizes rigorous quality control (QC) and in-lab cell qualification to ensure every batch performs consistently in real experimental setups. By meeting these stringent standards, our human hepatocytes deliver unmatched reliability in drug metabolism research.
Low-clearance compound metabolism remains a major challenge in DMPK. Preci has developed the most enduring suspension assay systems on the market, ensuring extended cell viability and optimal enzyme activity. Our innovative approach empowers researchers to achieve accurate and reproducible results, even for the toughest compounds.
At Preci, our human liver microsomes products are designed with a vision to standardize and simplify current approaches in drug metabolism studies. We focus on delivering a reliable, batch-independent assay system that ensures consistent results across experiments. By emphasizing rigorous quality control and reproducibility, our microsomes eliminate variability, providing researchers with a dependable tool to advance their studies with confidence. With every batch, we aim to empower the scientific community by streamlining workflows and setting a new benchmark for precision and reliability in DMPK research.
Applications
Phase I metabolic clearance
CYP inhibition
Metabolites identification
In drug metabolism and pharmacokinetics (DMPK) development, understanding the intricate processes of drug biotransformation and elimination is foundational to creating safe and effective therapies. Key biological tools—S9 fractions, cytosolic fractions, and lysosomes—serve as the cornerstone for these studies. These subcellular components represent essential biochemical environments where critical enzymatic reactions and drug interactions occur. By leveraging these systems, researchers can dissect complex metabolic pathways, predict drug behavior, and identify potential safety concerns early in the development process. Their fundamental role in mimicking in vivo conditions makes them indispensable in modern drug research and discovery.
In drug metabolism and pharmacokinetics (DMPK) development, understanding the intricate processes of drug biotransformation and elimination is foundational to creating safe and effective therapies. Key biological tools—S9 fractions, cytosolic fractions, and lysosomes—serve as the cornerstone for these studies. These subcellular components represent essential biochemical environments where critical enzymatic reactions and drug interactions occur. By leveraging these systems, researchers can dissect complex metabolic pathways, predict drug behavior, and identify potential safety concerns early in the development process. Their fundamental role in mimicking in vivo conditions makes them indispensable in modern drug research and discovery.
S9 fractions
These are subcellular fractions containing both cytosolic and microsomal enzymes. They are widely used to study Phase I and Phase II metabolism, offering insights into both oxidative metabolism (e.g., CYP-mediated reactions) and conjugation processes like glucuronidation or sulfation. S9 fractions provide a balanced model for evaluating the overall metabolic profile of a compound.
Cytosolic fractions
These contain enzymes exclusive to the cytosolic compartment, such as sulfotransferases (SULTs) and glutathione S-transferases (GSTs). They are crucial for studying Phase II conjugation reactions that enhance drug solubility and facilitate excretion. Cytosolic fractions are vital for evaluating the detoxification and clearance potential of new drug candidates.
Lysosomes
Lysosomes are intracellular organelles crucial for the degradation and recycling of biomolecules, including proteins like immunoglobulins (IgGs). In catabolic studies, lysosomes are used to investigate how drugs, especially biologics like monoclonal antibodies, are broken down within cells. These organelles house a variety of hydrolytic enzymes that facilitate the breakdown of complex molecules under acidic conditions, providing insights into the stability and clearance of therapeutic proteins.
For drug development, lysosomal studies are invaluable in understanding the degradation pathways of IgGs, optimizing drug stability, and predicting in vivo pharmacokinetics. Additionally, they help assess the potential for lysosomal storage or toxicity, which is critical for drugs that interact with or accumulate in lysosomes. This knowledge aids in designing more effective and safer therapies, particularly for biologics and lysosome-targeting drugs.
For too long, DMPK research has been confined by models designed for ease of production rather than the needs of scientists. Assays have been adapted to fit the limitations of what was simple to manufacture, prioritizing convenience over reliability, scalability, and real-world performance. At Preci, we saw this as a fundamental flaw—a barrier to progress—and took bold action to overturn this paradigm. We have developed a revolutionary system of products that are reliable, scalable, and reproducible, all while maintaining the scientific integrity of primary cells and subcellular fractions as the foundation for cutting-edge research.
Our first groundbreaking solution is a wide-ranging suspension system for metabolic clearance and metabolite identification (MetID). Unlike traditional methods constrained by production-friendly models, our system is designed for extended functionality, enabling the study of high-, medium-, and low-clearance compounds with unparalleled reliability. With metabolic activity sustained for up to 10 hours in culture, researchers can trust our system to deliver reproducible results, breaking free from the limitations of outdated approaches.
But this is just the beginning. The demands of modern DMPK research extend beyond metabolic studies, and Preci is leading the way with innovative tools for drug-drug interaction (DDI) assays and pre-plated microsome platforms. These products address the pressing need for consistency and scalability, offering researchers solutions that align with the highest scientific and industry standards.
By prioritizing application-focused systems over production-driven compromises, Preci has revolutionized how DMPK challenges are addressed. Our products are proof that primary cells and subcellular fractions can be harnessed in ways that are not only scientifically rigorous but also capable of transforming the landscape of drug metabolism research. This is the next evolution in DMPK—built for discovery, driven by reliability, and designed for the future.